Proatrial natriuretic peptide is a better predictor of 28-day mortality in septic shock patients than proendothelin-1

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 12, 2010, Pages 1813-1820

  Guignant, Caroline ^a   Venet, Fabienne ^a   Voirin, Nicolas ^a   Poitevin, Françoise ^a   Malcus, Christophe ^a   Bohé, Julien ^b   Lepape, Alain ^b   Monneret, Guillaume ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

atrial natriuretic factor; endothelin 1; mortality; prognosis; septic shock

Indexed keywords

ADRENALIN; ATRIAL NATRIURETIC FACTOR; C TERMNIAL PROENDOTHELIN 1; DOBUTAMINE; ENDOTHELIN DERIVATIVE; MIDREGIONAL PROATRIAL NATRIURETIC PEPTIDE; NORADRENALIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COMORBIDITY; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOLUMINOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SEPTIC SHOCK; SURVIVOR;

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; ENDOTHELIN-1; HUMANS; IMMUNOASSAY; MORTALITY; OBSERVATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN PRECURSORS; SHOCK, SEPTIC; SURVIVORS;

EID: 78951471770     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.341     Document Type: Article

References (34)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29, 1303-10.
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-54.
3. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 2007;35:1244-50.
4. Brun-Buisson C, Meshaka P, Pinton P, Vallet B. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004;30: 580-8.
5. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-96.
6. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.
7. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
8. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-24.
9. Marshall JC. Sepsis: rethinking the approach to clinical research. J Leukoc Biol 2008;83:471-82.
10. Marshall JC, Reinhart K, International Sepsis Forum. Biomarkers of sepsis. Crit Care Med 2009;37:2290-8.
11. Carlet J, Cohen J, Calandra T, Opal SM, Masur H. Sepsis: time to reconsider the concept. Crit Care Med 2008;36:964-6.
12. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-6.
13. Flierl MA, Rittirsch D, Huber-Lang MS, Sarma JV, Ward PA. Molecular events in the cardiomyopathy of sepsis. Mol Med 2008;14:327-36.
14. Matsuda N, Hattori Y. Vascular biology in sepsis: pathophysiological and therapeutic significance of vascular dysfunction. J Smooth Muscle Res 2007;43:117-37.
15. Shah R. Endothelins in health and disease. Eur J Intern Med 2007;18:272-82.
16. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8.
17. Schuetz P, Christ-Crain M, Morgenthaler NG, Struck J, Bergmann A, Müller B. Circulating precursor levels of endothelin- 1 and adrenomedullin, two endothelium-derived, counteracting substances, in sepsis. Endothelium 2007;14:345-51.
18. Morgenthaler NG, Struck J, Christ-Crain M, Bergmann A, Müller B. Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study. Crit Care 2005;9:R37-45.
19. Seligman R, Papassotiriou J, Morgenthaler NG, Meisner M, Teixeira PJ. Prognostic value of midregional pro-atrial natriuretic peptide in ventilator-associated pneumonia. Intensive Care Med 2008;34:2084-91.
20. Bone RC. Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome). J Am Med Assoc 1992;268:3452-5.
21. Monneret G, Lepape A, Voirin N, Bohé J, Venet F, Debard AL, et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 2006;32:1175-83.
22. Le Gall JR, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. J Am Med Assoc 1993;270:2957-63.
23. Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-relat ed problems" of the European Society of Intensive Care Medicine. Crit Care Med 1998;26:1793-800.
24. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004;50:234-6.
25. Papassotiriou J, Morgenthaler NG, Struck J, Alonso C, Bergmann A. Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma. Clin Chem 2006;52:1144-51.
26. Seidler T, Pemberton C, Yandle T, Espiner E, Nicholls G, Richards M. The amino terminal regions of proBNP and proANP oligomerise through leucine zipper-like coiled-coil motifs. Biochem Biophys Res Commun 1999;255:495-501.
27. Struck J, Morgenthaler NG, Bergmann A. Proteolytic processing pattern of the endothelin-1 precursor in vivo. Peptides 2005;26:2482-6.
28. Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. J Am Med Assoc 2001;286:1754-8.
29. Biomarkers Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
30. Parrillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, et al. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990;113:227-42.
31. Lee CY, Burnett JC Jr. Natriuretic peptides and therapeutic applications. Heart Fail Rev 2007;12:131-42.
32. Roch A, Allardet-Servent J, Michelet P, Oddoze C, Forel JM, Barrau K et al. NH2 terminal pro-brain natriuretic peptide plasma level as an early marker of prognosis and cardiac dysfunction in septic shock patients. Crit Care Med 2005;33:1001-7.
33. Varpula M, Pulkki K, Karlsson S, Ruokonen E, Pettila V. Predictive value of n-terminal pro-brain natriuretic peptide in severe sepsis and septic shock. Crit Care Med 2007;35:1277-83.
34. Guignant C, Voirin N, Venet F, Poitevin F, Malcus C, Bohé J, et al. Assessment of pro-vasopressin and pro-adrenomedullin as predictors of 28-day mortality in septic shock patients. Intensive Care Med 2009;35:1859-67.